Nona and Dragonfly enter HCAb-based drug discovery partnership

In an exciting collaboration, Nona and Dragonfly have come together to form a partnership focused on HCAb-based drug discovery. This innovative partnership aims to leverage the unique properties of heavy chain-only antibodies (HCAbs) to develop novel therapeutics for a range of diseases. In this blog post, we will delve into the key points surrounding the Nona and Dragonfly partnership and the potential impact it could have on drug discovery.

1. HCAb-Based Drug Discovery

HCAbs are a special type of antibodies found in camelids, such as camels or llamas. Unlike traditional antibodies found in humans and other species, HCAbs consist of only heavy chains, making them smaller and more versatile. The unique structure of HCAbs allows them to target specific disease markers with precision, making them promising candidates for therapy development.

2. Nona’s Expertise in HCAbs

Nona, a leading biotechnology company, specializes in the discovery and development of HCAb-based therapeutics. Their extensive expertise in HCAb engineering and optimization makes them a valuable partner in this collaboration. Nona’s research and development capabilities will be instrumental in advancing the therapeutic potential of HCAbs and translating them into effective treatments for various diseases.

3. Dragonfly’s Innovative Approach

Dragonfly, a biotechnology company renowned for its cutting-edge immunotherapy platforms, brings its expertise in identifying and targeting immune cell receptors to this partnership. Their innovative approach, known as TriNKET™ technology, enables the design of therapeutic products that harness the power of the immune system to combat diseases. By combining this expertise with Nona’s HCAb platform, Dragonfly aims to develop groundbreaking therapies with enhanced efficacy and precision.

4. Broad Applications in Disease Treatment

The Nona and Dragonfly partnership has the potential to impact the treatment of a wide range of diseases. HCAbs, with their unique properties and ability to target specific disease markers, offer immense possibilities in areas such as oncology, autoimmune disorders, infectious diseases, and more. This partnership could pave the way for the development of tailored, effective therapies that address unmet medical needs across various therapeutic areas.

5. Advancements in Precision Medicine

Precision medicine, an approach that tailors medical treatments to individual patients based on their unique characteristics, holds great promise for improving patient outcomes. The collaboration between Nona and Dragonfly aligns with this vision by leveraging the specificity and versatility of HCAbs to develop precise, targeted therapies. This partnership represents a step forward in realizing the potential of precision medicine and personalized treatment strategies.

6. Potential Impact on the Pharmaceutical Industry

The partnership between Nona and Dragonfly has the potential to disrupt the pharmaceutical industry by introducing a new class of therapeutics. By harnessing the power of HCAbs and combining it with Dragonfly’s innovative TriNKET™ technology, this collaboration could lead to the development of breakthrough drugs that are more efficacious, have fewer side effects, and provide better patient outcomes. The success of this partnership could inspire similar collaborations and further drive innovation in the field of drug discovery.


The partnership between Nona and Dragonfly in HCAb-based drug discovery marks an exciting development in the field of therapeutics. By combining their expertise in HCAb engineering and immunotherapy platforms, the collaboration aims to develop novel treatments for various diseases. This collaboration holds promise for advancing precision medicine, improving patient outcomes, and disrupting the pharmaceutical industry. As this partnership progresses, it could open new doors for innovative therapies and bring us closer to more effective and personalized treatments for a range of medical conditions.